title: The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly.
abstract: To determine if specific levels of vaccine cost and effectiveness exist that would support eventual respiratory syncytial virus (RSV) vaccine use in the elderly, a cost-effectiveness study was conducted comparing yearly administration of a hypothetical RSV vaccine among the 65-year-old US cohort to medical management of disease. Using base case assumptions - including a vaccine effectiveness against RSV-related hospitalization and death of 80% and a vaccine cost of US$33 - vaccine would result in 0.7 additional days of healthy life at a cost of US$9.82 per person. The cost per quality-adjusted life-year gained equaled US$5342 and remained reasonable over a wide range of vaccine cost and effectiveness. RSV vaccine would be cost-effective for the elderly population, with cost-effectiveness ratios similar to those for influenza vaccine.
authors.affiliation: Association Pour l'Aide à la Médecine Préventive. 3 Avenue Pasteur BP10, 92430, Marnes-la-Coquette, France. 106617.3011@compuserve.com
authors.forename: B D
authors.initials: BD
authors.lastname: Gessner
mesh_terms: D000367:Age Factors; D000368:Aged; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D006801:Humans; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D014765:Viral Vaccines